Correction: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

Documenti analoghi

• Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus
  di: Dörner, Thomas, et al.
  Pubblicazione: (2006)
• Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study
  di: Steinfeld, Serge D, et al.
  Pubblicazione: (2006)
• Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus
  di: Daridon, Capucine, et al.
  Pubblicazione: (2010)
• Efficacy of Epratuzumab, an Anti‐CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials
  di: Gottenberg, Jacques‐Eric, et al.
  Pubblicazione: (2018)
• Treatment of systemic lupus erythematosus with epratuzumab
  di: Traczewski, Pawel, et al.
  Pubblicazione: (2011)